"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Traderead more
On Sunday, the 71st Primetime Emmy Awards will honor the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
Gilead CEO John Milligan called on the pharmaceutical industry to do more amid criticism of drug pricing.
"I think we've done a bad job as an industry of being transparent. We haven't really talked about what is paid by the payer or paid by the patient," Milligan said on CNBC's "Fast Money" on Tuesday.
The biotech industry has been under intense scrutiny amid criticism from presidential hopefuls in the past year.
Sen. Bernie Sanders has called out individual pharmaceutical companies for raising prices on orphan drugs. Hillary Clinton was also vocal about the issue, taking down the price of a key biotech ETF in the wake of her comments. President-elect Donald Trump told Time magazine that he wants to bring down drug prices because he doesn't like what has happened with them.
The payment system in the United States is fragmented, which Milligan said "creates a disconnect between the price that's often published and the price that people pay." The Gilead CEO added he believes there's too much burden placed on the patient in the current system.